Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Viruses aren’t all bad: In the ocean, some help fuel the food web – a new study shows how - 2Don’t let food poisoning crash your Thanksgiving dinner
- 3Sentimental tree to shine at Arctic League annual broadcast
- 4AI’s errors may be impossible to eliminate – what that means for its use in health care
- 5NASA says Maven spacecraft that was orbiting Mars has gone silent
- Ariana Grande to host 'Saturday Night Live' Christmas show with Cher as musical guest, returning after nearly 40 years
- Huge Iranian missile fragments, intercepted by air defenses, lay scattered across Israel, West Bank
- These four astronauts could soon travel farther from Earth than anyone has gone before
- The 15 Most Powerful Forerunners in Business
- Step by step instructions to Recognize the Distinction Between Lab Jewels and Precious stone Simulants
- ‘Slender Man’ attacker back in custody. What we know about Morgan Geyser's disappearance and what happens next.
- 2024's Hot Games: Must-Play Titles of the Year
- Tasting America: An Excursion Through Darling Cheap Food Brands
- Vacation destinations in America
